Cardea SOLO™ ECG For Clinical Research
Cardea SOLO ECG is an all-inclusive wearable 7-day continuous cardiac monitoring system that will change the way you acquire and analyze ECG data for research.
Collecting ECG Data Is As Simple As…
Cardea SOLO Research Request
Get more information on Cardea SOLO for your research project.
Big Pharma & Academic Institutions Turn To Cardea SOLO For ECG Data Collection
Fast & Easy Application
The friendly SOLO Sensor design made it an easy choice for Pharma clients. The SOLO Sensor is lightweight, water-resistant, and wire-free. Research participants could be mailed a sensor for self-application to enable social distancing.
Local & Secure Data
The Cardea SOLO Analysis Software installs directly on your local PC and therefore your ECG data stays on your PC or private network — no transferring of data between your research team and a third party data analysis server. Get 100% access, 100% ECG data ownership, 100% of the time.
Where You Can Find Cardea SOLO In Research
Mobile Health Monitoring of Cardiac Status
Abstract 14160: Assessment of Atrial Fibrillation Burden by Smartwatch Photoplethysmography
Premature Atrial and Ventricular Contraction Detection Using Photoplethysmographic Data from a Smartwatch
Cardiac Insight, Inc. is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn ECG sensor technology and automated cardiac analysis solutions through its proprietary algorithms and software platforms. The company’s products include the Cardea SOLO™ wearable ECG Sensor and Software Analysis System as well as the Cardea 20/20 ECG™ – the only resting ECG System designed for cardiac risk screening in active youth and athletes at all levels of play. AFib is the most common type of treated heart arrhythmia, with an estimated 2.7 to 6.1 million people in the U.S. living with this arrhythmia. While AFib itself is typically not life-threatening, complications from AFib if left untreated include increased risk for heart problems and heart failure, and increased risk for stroke. AFib is responsible for about one in seven strokes.